Key Takeaways
- Cencora (COR) announced a definitive agreement to acquire the majority of the outstanding equity interests it does not already own in OneOncology for approximately $3.6 billion, significantly expanding its presence in community oncology.
- The transaction values the entire OneOncology enterprise at $7.4 billion and includes Cencora retiring $1.3 billion of OneOncology's existing corporate debt, bringing the total cash consideration to roughly $5.0 billion.
- Cencora reiterated its fiscal year 2026 adjusted diluted earnings per share (EPS) guidance in the range of $17.45 to $17.75, though it expects earnings to be towards the lower half of this range due to a pause in share repurchases to fund the acquisition.
- In parallel, the U.S. House of Representatives faces a critical week for healthcare policy, with Speaker Mike Johnson confronting a revolt from GOP moderates over the "Lower Health Care Premiums for All Americans Act" and the looming expiration of enhanced Affordable Care Act (ACA) premium tax credits.
Pharmaceutical solutions organization Cencora (COR) is set to deepen its involvement in the oncology sector, announcing a deal to acquire a majority stake in OneOncology for approximately $3.6 billion. This move builds upon Cencora's existing minority investment in the physician-led national platform, which supports independent medical specialty practices focused on oncology. The comprehensive transaction, which values OneOncology at an enterprise value of $7.4 billion, also involves Cencora retiring $1.3 billion of OneOncology's corporate debt, bringing the total cash outlay to an estimated $5.0 billion.
The acquisition is expected to close by the end of Cencora's fiscal 2026 second quarter, pending customary closing conditions and regulatory approvals. Cencora plans to finance the deal through new debt while aiming to maintain its investment-grade credit ratings. While the company reaffirmed its fiscal year 2026 adjusted diluted EPS guidance of $17.45 to $17.75, it noted that earnings would likely trend towards the lower end of this forecast due to a temporary halt in share repurchases to facilitate the funding. However, Cencora has also raised its long-term guidance, projecting adjusted operating income growth of 7% to 10% and adjusted diluted EPS growth of 10% to 14%.
The healthcare landscape is also seeing significant political developments. House Speaker Mike Johnson is navigating a challenging week as GOP moderates express dissent over his proposed "Lower Health Care Premiums for All Americans Act." This legislative effort comes as enhanced Obamacare premium tax credits are set to expire on December 31, threatening to push millions of Americans into losing health insurance or facing substantially higher premiums.
The internal Republican division is highlighted by a discharge petition introduced by GOP moderates, including Rep. Brian Fitzpatrick (R-Pa.), aiming to force a vote on extending the Affordable Care Act subsidies. This political infighting suggests a potential "Obamacare cliff" is imminent, with both parties reportedly prioritizing internal reasons over a bipartisan solution, a development that could have significant personal and political ramifications heading into the 2026 election cycle.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.